WO2002006221A3 - Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists - Google Patents
Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists Download PDFInfo
- Publication number
- WO2002006221A3 WO2002006221A3 PCT/US2001/022359 US0122359W WO0206221A3 WO 2002006221 A3 WO2002006221 A3 WO 2002006221A3 US 0122359 W US0122359 W US 0122359W WO 0206221 A3 WO0206221 A3 WO 0206221A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclylamine
- sulfonamides
- beta
- receptor agonists
- adrenergic receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002512127A JP2004504296A (en) | 2000-07-17 | 2001-07-16 | Cycylamine sulfonamides as beta-3 adrenergic receptor agonists |
BR0112582-6A BR0112582A (en) | 2000-07-17 | 2001-07-16 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
AU2002222929A AU2002222929A1 (en) | 2000-07-17 | 2001-07-16 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
MXPA03000450A MXPA03000450A (en) | 2000-07-17 | 2001-07-16 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists. |
EP01984233A EP1328512A2 (en) | 2000-07-17 | 2001-07-16 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
CA002416667A CA2416667A1 (en) | 2000-07-17 | 2001-07-16 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21876400P | 2000-07-17 | 2000-07-17 | |
US60/218,764 | 2000-07-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002006221A2 WO2002006221A2 (en) | 2002-01-24 |
WO2002006221A3 true WO2002006221A3 (en) | 2002-06-13 |
Family
ID=22816416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/022359 WO2002006221A2 (en) | 2000-07-17 | 2001-07-16 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
Country Status (10)
Country | Link |
---|---|
US (2) | US6498170B2 (en) |
EP (1) | EP1328512A2 (en) |
JP (1) | JP2004504296A (en) |
CN (1) | CN1455769A (en) |
AR (1) | AR032466A1 (en) |
AU (1) | AU2002222929A1 (en) |
BR (1) | BR0112582A (en) |
CA (1) | CA2416667A1 (en) |
MX (1) | MXPA03000450A (en) |
WO (1) | WO2002006221A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK285908B6 (en) * | 1998-04-01 | 2007-10-04 | Nortran Pharmaceuticals Inc. | Aminocyclohexyl ether compound, composition comprising it and use thereof in the manufacture of medicaments and in the treatment of diseases |
US6979685B1 (en) * | 1999-02-12 | 2005-12-27 | Cardiome Pharma Corp. | Cycloalkyl amine compounds and uses thereof |
US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
US6410734B1 (en) * | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US7057053B2 (en) * | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US7524879B2 (en) * | 2000-10-06 | 2009-04-28 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US6376514B1 (en) * | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
US6693099B2 (en) * | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
US6885903B2 (en) * | 2001-07-10 | 2005-04-26 | General Electric Company | Method and system for tracking repair of components |
US6856733B2 (en) * | 2001-12-07 | 2005-02-15 | Intel Corporation | 1xN fanout waveguide photodetector |
US7345086B2 (en) * | 2003-05-02 | 2008-03-18 | Cardiome Pharma Corp. | Uses of ion channel modulating compounds |
NZ543921A (en) * | 2003-05-02 | 2008-11-28 | Cardiome Pharma Corp | Aminocyclohexyl ether compounds and uses thereof |
US20090041841A1 (en) * | 2003-05-02 | 2009-02-12 | Cardiome Pharma Corp. | Controlled release tablet formulations for the prevention of arrhythmias |
US7674820B2 (en) * | 2003-08-07 | 2010-03-09 | Cardiome Pharma Corp. | Ion channel modulating activity I |
US7345087B2 (en) * | 2003-10-31 | 2008-03-18 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
US7977373B2 (en) | 2004-04-01 | 2011-07-12 | Cardiome Pharma Corp. | Prodrugs of ion channel modulating compounds and uses thereof |
US8058304B2 (en) * | 2004-04-01 | 2011-11-15 | Cardiome Pharma Corp. | Merged ion channel modulating compounds and uses thereof |
US7572792B2 (en) * | 2004-04-29 | 2009-08-11 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
CA2586918C (en) * | 2004-11-08 | 2021-01-19 | Cardiome Pharma Corp. | Use of ion channel modulating compounds for treating acute atrial fibrillation in a human |
US20070054590A1 (en) * | 2005-08-24 | 2007-03-08 | Schmidt Christopher B | Photo-chromic toys |
WO2007037187A1 (en) | 2005-09-27 | 2007-04-05 | Shionogi & Co., Ltd. | Sulfonamide derivative having pgd2 receptor antagonistic activity |
CA2625219A1 (en) * | 2005-10-13 | 2007-04-19 | Orchid Research Laboratories Limited | Heterocyclic compounds as pstat3/il-6 inhibitors |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
WO2011025690A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2163150A (en) * | 1984-07-19 | 1986-02-19 | Sandoz Ltd | 3-Aminopropoxyaryl derivatives |
WO1995029159A1 (en) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
WO1997046556A1 (en) * | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
EP0827746A1 (en) * | 1996-09-05 | 1998-03-11 | Eli Lilly And Company | Carbazole analogues as selective B3 adrenergic agonists |
WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
WO1998032753A1 (en) * | 1997-01-28 | 1998-07-30 | Merck & Co., Inc. | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
EP0940387A1 (en) * | 1995-10-26 | 1999-09-08 | Tokyo Tanabe Company Limited | Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same |
FR2780057A1 (en) * | 1998-06-18 | 1999-12-24 | Sanofi Sa | PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
FR2798126A1 (en) * | 1999-09-08 | 2001-03-09 | Sanofi Synthelabo | HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348393A (en) | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
US4775670A (en) * | 1980-09-29 | 1988-10-04 | E. R. Squibb & Sons, Inc. | 2-oxo-1-azetidinesulfonic acid salts |
EP0089154A3 (en) | 1982-03-12 | 1984-08-08 | Beecham Group Plc | Ethanolamine derivatives, their preparation and use in pharmaceutical compositions |
US4499100A (en) * | 1983-05-18 | 1985-02-12 | Syntex (U.S.A.) Inc. | Benzodioxanyl-hydroxyethyleneamino-piperidinyl acetanilides, ketones, esters and carbamates which effect immunity and calcium entry and β-blockade |
GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
US4813998A (en) | 1986-02-27 | 1989-03-21 | Janssen Pharmaceutica N.V. | Herbicidal 1H-imidazole-5-carboxylic acid derivatives |
EP0449261A3 (en) | 1990-03-29 | 1992-02-26 | Kabushiki Kaisha Toshiba | Resin composition for an optical disc and an optical disc using it |
DK0590793T3 (en) | 1992-08-31 | 2000-01-31 | Sankyo Co | Oxazolidine derivatives with anti-diabetic and anti-obesity properties, their preparation and their therapeutic use |
US5998452A (en) | 1993-06-23 | 1999-12-07 | Chugai Seiyaku Kabushiki Kaisha | Benzene derivatives, compositions and methods for treating ischemic diseases |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
IL113084A (en) | 1994-03-23 | 1999-01-26 | Sankyo Co | Thiazolidine and oxazolidine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5614523A (en) | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5789402A (en) | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
WO1997041120A1 (en) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
US6150378A (en) | 1997-10-07 | 2000-11-21 | Cephalon, Inc. | Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors |
ID23989A (en) | 1997-10-17 | 2000-06-14 | Yamanouchi Pharma Co Ltd | THE AMIDA DOWNS OR THE SALT |
US6214842B1 (en) | 1999-05-12 | 2001-04-10 | Michael S. Malamas | Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia |
FR2802533B1 (en) | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | PHENOXYPROPANOLAMINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2001043744A1 (en) | 1999-12-17 | 2001-06-21 | Sanofi-Synthelabo | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
US6509358B2 (en) | 2000-07-17 | 2003-01-21 | Wyeth | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6458817B1 (en) | 2000-07-17 | 2002-10-01 | Wyeth | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists |
US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6444685B1 (en) | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
US6514991B2 (en) | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
-
2001
- 2001-07-12 US US09/904,158 patent/US6498170B2/en not_active Expired - Fee Related
- 2001-07-16 AU AU2002222929A patent/AU2002222929A1/en not_active Abandoned
- 2001-07-16 CA CA002416667A patent/CA2416667A1/en not_active Abandoned
- 2001-07-16 JP JP2002512127A patent/JP2004504296A/en active Pending
- 2001-07-16 BR BR0112582-6A patent/BR0112582A/en not_active Application Discontinuation
- 2001-07-16 WO PCT/US2001/022359 patent/WO2002006221A2/en not_active Application Discontinuation
- 2001-07-16 AR ARP010103379A patent/AR032466A1/en unknown
- 2001-07-16 CN CN01815501A patent/CN1455769A/en active Pending
- 2001-07-16 EP EP01984233A patent/EP1328512A2/en not_active Withdrawn
- 2001-07-16 MX MXPA03000450A patent/MXPA03000450A/en unknown
-
2002
- 2002-09-05 US US10/235,911 patent/US6649603B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2163150A (en) * | 1984-07-19 | 1986-02-19 | Sandoz Ltd | 3-Aminopropoxyaryl derivatives |
WO1995029159A1 (en) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
EP0940387A1 (en) * | 1995-10-26 | 1999-09-08 | Tokyo Tanabe Company Limited | Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same |
EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
WO1997046556A1 (en) * | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
EP0827746A1 (en) * | 1996-09-05 | 1998-03-11 | Eli Lilly And Company | Carbazole analogues as selective B3 adrenergic agonists |
WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
WO1998032753A1 (en) * | 1997-01-28 | 1998-07-30 | Merck & Co., Inc. | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
FR2780057A1 (en) * | 1998-06-18 | 1999-12-24 | Sanofi Sa | PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
FR2798126A1 (en) * | 1999-09-08 | 2001-03-09 | Sanofi Synthelabo | HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Also Published As
Publication number | Publication date |
---|---|
CA2416667A1 (en) | 2002-01-24 |
AR032466A1 (en) | 2003-11-12 |
WO2002006221A2 (en) | 2002-01-24 |
BR0112582A (en) | 2003-05-20 |
US20030027797A1 (en) | 2003-02-06 |
EP1328512A2 (en) | 2003-07-23 |
AU2002222929A1 (en) | 2002-01-30 |
US6649603B2 (en) | 2003-11-18 |
CN1455769A (en) | 2003-11-12 |
JP2004504296A (en) | 2004-02-12 |
US6498170B2 (en) | 2002-12-24 |
MXPA03000450A (en) | 2003-06-06 |
US20020022605A1 (en) | 2002-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002006221A3 (en) | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | |
EP1630157A4 (en) | CaSR ANTAGONIST | |
WO2004048345A3 (en) | 2,5-diketopiperazines for the treatment of obesity | |
AP1614A (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents. | |
WO2000054765A8 (en) | Method of treating eating disorders | |
WO2002100860A3 (en) | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as anti-bacterial agents | |
MXPA04001500A (en) | Compounds effecting glucokinase. | |
CA2382480A1 (en) | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | |
CA2429844A1 (en) | Mch antagonists and their use in the treatment of obesity | |
WO2004106279A3 (en) | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | |
BR0307351A (en) | Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound | |
WO2003093269A3 (en) | Substituted pyrazolo-pyrimidine-4-ones | |
WO2005121097A3 (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
EP1741712A3 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol | |
AU2003229772A1 (en) | Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators | |
SE0201544D0 (en) | Novel compounds and thier use | |
WO2003024928A3 (en) | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives | |
HK1155146A1 (en) | Indene derivatives as pharmaceutical agents | |
WO2003014079A8 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
WO2006027798A3 (en) | A process for preparation of an antidepressant compound | |
TW200505823A (en) | CaSR antagonist | |
AU2003239389A1 (en) | Opioid receptor antagonists | |
WO2005058890A3 (en) | Hydronopol derivatives as agonists on human orl1 receptors | |
PT1222159E (en) | INTERMEDIARIES FOR THE MANUFACTURE OF A BENZOFURAN OR BENZOYOPHENE TYPE DERIVED NITRATED IN POSITION 5 AND ITS UTILIZATIONS | |
WO2003053971A8 (en) | Pyridoquinoxaline antivirals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002126611 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001984233 Country of ref document: EP Ref document number: 2416667 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/000450 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018155014 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001984233 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001984233 Country of ref document: EP |